Literature DB >> 13473045

Hemodynamic aspects of diffuse myocardial fibrosis.

E D ROBIN, C S BURWELL.   

Abstract

Entities:  

Keywords:  MYOCARDIUM/diseases

Mesh:

Year:  1957        PMID: 13473045     DOI: 10.1161/01.cir.16.5.730

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  10 in total

1.  CARDIAC FUNCTION IN PRIMARY MYOCARDIAL DISORDERS II.

Authors:  J F GOODWIN
Journal:  Br Med J       Date:  1964-06-20

2.  [FAMILIAL CARDIOMEGALY ON THE BASIS OF ENDOMYOCARDIAL FIBROSIS].

Authors:  H J HAUCH; W LANGE; M NITSCHKE
Journal:  Arch Kreislaufforsch       Date:  1964-07

3.  [On the diagnosis, differential diagnosis and hemodynamics of constrictive pericarditis, so-called idiopathic myocardial hypertrophy and endocardial fibrosis with special reference to catheterization of the left and right heart and selective levocardiography].

Authors:  H H HILGER; A SCHAEDE; A DUEX; P THURN
Journal:  Arch Kreislaufforsch       Date:  1962-08

4.  [Unusual heart diseases of unknown genesis; endomyocardial fibrosis, familial cardiomegly, idiopathic myocarditis].

Authors:  W HADORN; P MUELLER
Journal:  Arch Kreislaufforsch       Date:  1961-07

5.  Clinical aspects of cardiomyopathy.

Authors:  J F GOODWIN; H GORDON; A HOLLMAN; M B BISHOP
Journal:  Br Med J       Date:  1961-01-14

6.  The interpretation of pulmonary artery wedge (pulmonary capillary) pressures.

Authors:  W H BERNSTEIN; E M FIERER; M H LASZLO; P SAMET; R S LITWAK
Journal:  Br Heart J       Date:  1960-01

7.  SUBENDOCARDIAL FIBROELASTOSIS IN AN ADULT WOMAN.

Authors:  J de L Mignault; C Goulet; F Gagne; J H Laliberte
Journal:  Can Med Assoc J       Date:  1959-09-15       Impact factor: 8.262

8.  [Essential myocardiopathy].

Authors:  E J Haupt; J Schmidt
Journal:  Arch Kreislaufforsch       Date:  1968-01

Review 9.  Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here.

Authors:  Tiago Tribolet de Abreu
Journal:  Heart Fail Rev       Date:  2022-05-23       Impact factor: 4.654

10.  Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System In Vivo to Treat Heart Disease.

Authors:  Joel G Rurik; Jonathan A Epstein
Journal:  DNA Cell Biol       Date:  2022-04-20       Impact factor: 3.550

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.